Martin Sramek1, Jakub Neradil1, Renata Veselska2. 1. International Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno 656 91, Czech Republic. 2. International Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, Brno 656 91, Czech Republic. Electronic address: veselska@sci.muni.cz.
Abstract
BACKGROUND: For decades, methotrexate (MTX; amethopterin) has been known as an antifolate inhibitor of dihydrofolate reductase (DHFR), and it is widely used for the treatment of various malignancies and autoimmune diseases. Although the inclusion of MTX in various therapeutic regimens is based on its ability to inhibit DHFR and consequently to suppress the synthesis of pyrimidine and purine precursors, recent studies have shown that MTX is also able to target other intracellular pathways that are independent of folate metabolism. SCOPE OF REVIEW: The main aim of this review is to summarize the most important, up-to-date findings of studies regarding the non-DHFR-mediated mechanisms of MTX action. MAJOR CONCLUSIONS: The effectiveness of MTX is undoubtedly caused by its capability to affect various intracellular pathways at many levels. Although the most important therapeutic mechanism of MTX is strongly based on the inhibition of DHFR, many other effects of this compound have been described and new studies bring new insights into the pharmacology of MTX every year. GENERAL SIGNIFICANCE: Identification of these new targets for MTX is especially important for a better understanding of MTX action in new protocols of combination therapy.
BACKGROUND: For decades, methotrexate (MTX; amethopterin) has been known as an antifolate inhibitor of dihydrofolate reductase (DHFR), and it is widely used for the treatment of various malignancies and autoimmune diseases. Although the inclusion of MTX in various therapeutic regimens is based on its ability to inhibit DHFR and consequently to suppress the synthesis of pyrimidine and purine precursors, recent studies have shown that MTX is also able to target other intracellular pathways that are independent of folate metabolism. SCOPE OF REVIEW: The main aim of this review is to summarize the most important, up-to-date findings of studies regarding the non-DHFR-mediated mechanisms of MTX action. MAJOR CONCLUSIONS: The effectiveness of MTX is undoubtedly caused by its capability to affect various intracellular pathways at many levels. Although the most important therapeutic mechanism of MTX is strongly based on the inhibition of DHFR, many other effects of this compound have been described and new studies bring new insights into the pharmacology of MTX every year. GENERAL SIGNIFICANCE: Identification of these new targets for MTX is especially important for a better understanding of MTX action in new protocols of combination therapy.
Authors: Rakesh K Singh; Leon van Haandel; Daniel P Heruth; Shui Q Ye; J Steven Leeder; Mara L Becker; Ryan S Funk Journal: J Pharmacol Exp Ther Date: 2018-02-02 Impact factor: 4.030
Authors: Michele Tonelli; Lieve Naesens; Sabrina Gazzarrini; Matteo Santucci; Elena Cichero; Bruno Tasso; Anna Moroni; Maria Paola Costi; Roberta Loddo Journal: Eur J Med Chem Date: 2017-04-27 Impact factor: 6.514
Authors: Abdulla Y Al-Taher; Mohamed A Morsy; Rehab A Rifaai; Nagwa M Zenhom; Seham A Abdel-Gaber Journal: Mediators Inflamm Date: 2020-02-10 Impact factor: 4.711
Authors: Manjunath P Pai; Kenneth C Debacker; Brian Derstine; June Sullivan; Grace L Su; Stewart C Wang Journal: Pharmacotherapy Date: 2020-03-27 Impact factor: 4.705